Testing a drug called BRiTE for grade 4 glioblastoma
Original title: BRiTE - Bispecific T Cell Engager for Patients With Glioblastoma
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is an early test to check how safe the drug is in people.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This study is testing a new drug for a brain tumor called glioblastoma: The fastest-growing type of glioma (grade 4). Treatment usually starts soon after diagnosis: surgery first, then radiation and chemotherapy. See the glossary.
Who this trial is for. This trial tests a drug called BRiTE in people with WHO Grade 4 glioblastoma: The fastest-growing type of glioma (grade 4). Treatment usually starts soon after diagnosis: surgery first, then radiation and chemotherapy. See the glossary. The tumor can be new or have come back, and it must have a change called EGFRvIII.
Where it stands. This trial has not reported results. It is checking how safe BRiTE is and how well people handle it. It is also looking for the highest dose people can take. The drug is given into a vein for 4 days (96 hours) in a 28-day cycle. The answers are not in yet.
What this means, and what it doesn't
What it could mean: Right now we do not know if BRiTE helps people with this tumor. Someone whose tumor fits this picture could ask their care team about it. The care team can go over the risks and what taking part would involve.
What it doesn't mean: This does not mean BRiTE works. A trial is a test, not a proven treatment. Joining a trial does not promise any benefit. This is not a cure.
Source: ClinicalTrials.gov, August 18, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.